From The Motley Fool · Prosper Junior Bakiny · · 1m 10s
Revolution Medicines Drug Targets 'Undruggable' Cancer
Revolution Medicines' Rasonque, the first drug to target RAS-addicted cancers, generated $198 million in five weeks.
In brief
Revolution Medicines' Rasonque, the first drug to target RAS-addicted cancers, generated $198 million in five weeks. Revolution Medicines' Rasonque achieved the strongest oncology drug launch in history with $198 million revenue in five weeks. Originally reported by The Motley Fool.
Rasonque Approval

Revolution Medicines earned approval for Rasonque, a medicine for pancreatic cancer targeting RAS-addicted cancers.
Strong Launch
Rasonque generated $198 million in five weeks, marking the strongest oncology drug launch on record.
Clinical Results
Rasonque led to a median overall survival of 13.2 months versus 6.7 months with chemotherapy in Phase 3 trials.
RAS-Addicted Cancers
RAS-addicted cancers account for 20% to 30% of all human cancers, making Rasonque's target historically undruggable.
Pipeline Progress
Revolution Medicines has eight Phase 3 clinical trials, including two investigational medicines, zoldonrasib and elironrasib.
Market Reaction
Shares rose 100% this year after Rasonque's approval, but declined 29% since launch despite strong sales.
Valuation Justification
The company's $34.8 billion market cap is justified by potential $3 billion in next year's revenue and 11.6x sales valuation.
The takeaway
Revolution Medicines' Rasonque achieved the strongest oncology drug launch in history with $198 million revenue in five weeks.
Read the TL;DR — this story on one card.





